ABIONYX Pharma Provides an Update on Its Business and Cash Position for the First Half of 2023
17 Agosto 2023 - 1:00PM
Business Wire
- Cash of €1.9 million (excluding Research Tax Credit) as of
June 30, 2023
Regulatory News:
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible),
a new generation biotech company dedicated to the discovery and
development of innovative therapies based on the world's only
natural recombinant ApoA-I, today provided an update on its
business and cash position for the 1st half to June 30, 2023.
The company recorded consolidated half-year sales of €2.1
million, after elimination of intra-group transactions. IRIS Pharma
recorded half-year sales of €2.4 million.
At June 30, 2023, ABIONYX Pharma's cash position stood at €1.9
million, before receipt of the Research Tax Credit of ABIONYX
Pharma and IRIS Pharma.
Since the beginning of the year, the company has successfully
completed its first two batches of GMP (Good Manufacturing
Practice) industrial biomanufacturing of CER-001 using an
innovative and robust method. ABIONYX thus confirms its ability to
produce batches using the new production chain linked to an
innovative and efficient approach based on recombinant ApoA-I
protein.
To support this strategic biomanufacturing opportunity, the
company has chosen to set up an equity-linked financing facility to
secure a maximum investment of 12 million euros over the next two
years. Under the terms of the agreement, IRIS has committed to
finance the Company up to a maximum amount of €12,000,000 for a
period of 24 months by subscribing to a maximum of 4,800 bonds
redeemable in shares to be issued with a par value of €2,500 each,
in twenty (20) tranches of €600,000, (i.e. €570,000 Net) each
represented by 240 bonds. A second tranche of €600,000 was
subscribed early August via the exercise of 240 warrants to issue
bonds redeemable in new shares.
ABIONYX Pharma is developing two innovative technological
platforms: apotherapy only based on the apoA-I and biovectorization
using apoA-I complexes as a vector to deliver several active
ingredients. These two platforms have multiple possible
applications in ophthalmology.
ABIONYX Pharma has chosen to focus its apotherapy approach
initially on the ultra-rare LCAT disease, known as Norum's disease,
and on uveitis. ABIONYX Pharma's drug candidates for LCAT and
uveitis, CER-001 and ABNX-100, respectively, are intended to be
administered as systemic intravenous injections to target patients
with corneal opacity or ocular inflammation in the setting of
uveitis to achieve significant functional 2/3 visual improvement.
Last July, the company was granted Compassionate Access
Authorization (CAA) in Europe for a fourth patient suffering from
LCAT deficiency, known as Norum's disease.
Next financial release: 2023 Half-year results, September
28, 2023
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company that aims to
contribute to health through innovative therapies in indications
where there is no effective or existing treatment, even the rarest
ones. Thanks to its partners in research, medicine,
biopharmaceuticals and shareholding, the company innovates on a
daily basis to propose drugs for the treatment of renal and
ophthalmological diseases, or new HDL vectors used for targeted
drug delivery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230817887214/en/
NewCap Investor relations Louis-Victor Delouvrier Nicolas
Fossiez abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 94 98
Abionyx Pharma (EU:ABNX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Abionyx Pharma (EU:ABNX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024